Bristol-Myers Squibb Company (NYSE:BMY) is among the 15 Best High Yield Stocks to Buy, according to a recent report. UBS upgraded BMY to a Buy from Neutral, raising its price target to $65. The biotech and pharma sector is showing signs of recovery with a more supportive macro backdrop and stronger fundamentals.

While Bristol Myers has faced challenges, including patent cliffs, the company has a robust product lineup and is focusing on protecting its blockbuster brands. Recent approvals, like a subcutaneous version of Opdivo, and a pipeline of newer compounds, including one targeting Alzheimer’s disease, show promise for future growth.

Bristol-Myers Squibb Company is a global biopharma company dedicated to developing medicines for serious diseases. Despite the potential of BMY as an investment, some AI stocks may offer greater upside potential and lower downside risk.

For more investment options, check out the 13 Best Dividend Kings to Buy in 2026 and the 14 Best Mid Cap Dividend Aristocrat Stocks to Buy Now. Disclosure: None.

Read more at Yahoo Finance: UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery